OR WAIT null SECS
© 2022 MJH Life Sciences and BioPharm International. All rights reserved.
© 2022 MJH Life Sciences™ and BioPharm International. All rights reserved.
Cynthia A. Challener, PhD, is a contributing editor to BioPharm International.
Some progress has been made, but improvements are needed when harvesting cells for cell therapies.
Battles against antibiotic-resistant bacteria can be won with bacteriophages.
With high-concentration biologics, careful selection of excipients in formulation is crucial for reducing viscosity without destabilizing the protein.
The need to increase efficiency and productivity is driving adoption.
Careful selection is essential for achieving viscosity reduction without protein destabilization.
Analytical approaches must keep pace to ensure the identity, safety, and efficacy of evolving mRNA candidates.
Multispecific analysis is complex but can be achieved using appropriate strategies.
Timing is everything, and it might be ideal for acceleration of real-time monitoring solutions.
Surrogate analytics are no longer sufficient, as simple inexpensive real-time analytics are urgently needed for high value products.
Speed-to-market, capacity, technology development, and increased investment top the list.